2022
The Coming of Age of Preclinical Models of MDS
Liu W, Teodorescu P, Halene S, Ghiaur G. The Coming of Age of Preclinical Models of MDS. Frontiers In Oncology 2022, 12: 815037. PMID: 35372085, PMCID: PMC8966105, DOI: 10.3389/fonc.2022.815037.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsTranscription factorsEpigenetic modifiersComplex molecular landscapeXenograft modelHematopoietic cellsDeletions/additionsMolecular landscapeRecurrent mutationsCell linesGenetic abnormalitiesMDS cellsXenograft murine modelChromosomal abnormalitiesCellsIneffective hematopoiesisTransgenicHematopoiesisMutationsPreclinical modelsWide spectrumMurine modelHeterogeneous groupLandscapeComing of age
2018
SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells
Liang Y, Tebaldi T, Rejeski K, Joshi P, Stefani G, Taylor A, Song Y, Vasic R, Maziarz J, Balasubramanian K, Ardasheva A, Ding A, Quattrone A, Halene S. SRSF2 mutations drive oncogenesis by activating a global program of aberrant alternative splicing in hematopoietic cells. Leukemia 2018, 32: 2659-2671. PMID: 29858584, PMCID: PMC6274620, DOI: 10.1038/s41375-018-0152-7.Peer-Reviewed Original ResearchConceptsSplicing factorsRNA processingAlternative splicingGene productsSplicing factor SRSF2Gene regulatory eventsAberrant alternative splicingSplice alterationsRecurrent mutationsSplicing proteinsHITS-CLIPSR familyMRNA splicingSplicing genesHematopoietic differentiationRegulatory eventsImpairs hematopoietic differentiationMolecular explanationWidespread modificationSplicingHematopoietic cellsMutationsBinding eventsOncogenesisProtein